Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Della Corte

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinibMargherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Cancer Management and Research|January 7, 2022
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in ItalyValentina Burgio, Massimo Iavarone, Giovanni Giuseppe Di Costanzo, et al.
Oncology|January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide populationAndrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinibMargherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Cancer Management and Research|January 7, 2022
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in ItalyValentina Burgio, Massimo Iavarone, Giovanni Giuseppe Di Costanzo, et al.
Oncology|January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide populationAndrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, et al.
Pageof 3